SCHEMBL2471602

SCHEMBL2471602

CCOP(=O)(O)OCCN(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MVD P53602 1/20 0.42
PPARD Q03181 2/20 0.38
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM5 P08912 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRNB2 P17787 1/20 0.38
CHRM3 P20309 1/20 0.38
CHRNA4 P43681 1/20 0.38
TSHR P16473 2/20 0.37
ACHE P22303 1/20 0.35
TP53 P04637 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
DNM1 Q05193 1/20 0.34
GGPS1 O95749 2/20 0.34
CA12 O43570 2/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA9 Q16790 2/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27703224 0.98 MVD (0.41) MVDPPARDCHRM2CHRM4CHRM5
SCHEMBL17676824 0.88 ALDH1A1 (0.39) MVDPPARDTSHRGGPS1CA12
SCHEMBL2628074 0.88 MVD (0.42) MVDCHRM2CHRM4CHRM5CHRM1
SCHEMBL14365954 0.84 MVD (0.47) MVDPPARDTSHRACHETP53
SCHEMBL14750297 0.83 MVD (0.42) MVDPPARDCHRM2CHRM4CHRM5
SCHEMBL12914746 0.82 TSHR (0.48) PPARDTSHRTP53TDP1CA12
SCHEMBL24021282 0.81 LPAR3 (0.58) DNM1LPAR1LPAR3
SCHEMBL17817012 0.81 LPAR3 (0.58) DNM1LPAR1LPAR3
SCHEMBL14355841 0.81 LPAR3 (0.58) DNM1LPAR1LPAR3
SCHEMBL8232301 0.81 MVD (0.43) MVDCHRM2CHRM4CHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2598500-B1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY RIGEL PHARMACEUTICALS INC (US) 2021-05-19 EP disclosed
US-9920041-B2 Compositions and methods for inhibition of the JAK pathway RIGEL PHARMACEUTICALS, INC. (US) 2018-03-20 US disclosed
US-20170158683-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY RIGEL PHARMACEUTICALS, INC. (US) 2017-06-08 US disclosed
US-9611260-B2 Compositions and methods for inhibition of the JAK pathway RIGEL PHARMACEUTICALS, INC. (US) 2017-04-04 US disclosed
US-20160022622-A1 LIPID COMPOSITIONS CONTAINING BIOACTIVE FATTY ACIDS SCIADONICS, INC. 2016-01-28 US disclosed
US-20160024125-A1 NATURAL LIPIDS CONTAINING NON-OXIDIZABLE FATTY ACIDS BERGEN TEKNOLOGIOVERFØRING AS (NO) 2016-01-28 US disclosed
US-20150259332-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY RIGEL PHARMACEUTICALS, INC. (US) 2015-09-17 US disclosed
US-9067925-B2 Compositions and methods for inhibition of the JAK pathway RIGEL PHARMACEUTICALS, INC. (US) 2015-06-30 US disclosed
EP-2711369-A1 Liposomes containing tetraether lipid derivatives Bernina Plus GmbH (DE) 2014-03-26 EP disclosed
US-20130090310-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY RIGEL PHARMACEUTICALS, INC. (US) 2013-04-11 US disclosed
US-20090047596-A1 Donor element with release-modifier for thermal transfer E. I. DU PONT DE NEMOURS AND COMPANY 2009-02-19 US disclosed
US-7387864-B2 Donor element for thermal transfer E.I. DU PONT DE NEMOURS AND COMPANY (US) 2008-06-17 US disclosed
US-20080090169-A1 Composite Film Suitable as a Donor Support in a Radiation-Induced Thermal Transfer Imaging Process DUPONT TEIJIN FILMS U.S. LIMITED PARTNERSHIP (DE) 2008-04-17 US disclosed
US-20080003519-A1 Donor Element for Thermal Transfer E. I. DU PONT DE NEMOURS AND COMPANY 2008-01-03 US disclosed
EP-1805035-A1 COMPOSITE FILM SUITABLE AS A DONOR SUPPORT IN A RADIATION-INDUCED THERMAL TRANSFER IMAGING PROCESS Dupont Teijin Films U.S. Limited Partnership (US) 2007-07-11 EP disclosed
EP-1805034-A1 DONOR ELEMENT FOR THERMAL TRANSFER E.I. DUPONT DE NEMOURS AND COMPANY (US) 2007-07-11 EP disclosed
EP-1802471-A1 DONOR ELEMENT FOR RADIATION-INDUCED THERMAL TRANSFER E.I. DUPONT DE NEMOURS AND COMPANY (US) 2007-07-04 EP disclosed
WO-2006043072-A1 COMPOSITE FILM SUITABLE AS A DONOR SUPPORT IN A RADIATION-INDUCED THERMAL TRANSFER IMAGING PROCESS DUPONT TEIJIN FILMS U.S. LIMITED PARTNERSHIP (US) 2006-04-27 WO disclosed
WO-2006045083-A1 DONOR ELEMENT FOR RADIATION-INDUCED THERMAL TRANSFER E.I. DUPONT DE NEMOURS AND COMPANY (US) 2006-04-27 WO disclosed
WO-2006045085-A1 DONOR ELEMENT FOR THERMAL TRANSFER E.I. DUPONT DE NEMOURS AND COMPANY (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259332-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY JAK3, JAK2, JAK1 MVD 1723/4885PPARD 3635/4885CHRM2 4857/4885
US-20160024125-A1 NATURAL LIPIDS CONTAINING NON-OXIDIZABLE FATTY ACIDS FASN, ELOVL1, FADS1 MVD 1948/4885PPARD 287/4885CHRM2 4805/4885
US-20130090310-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY JAK3, JAK2, JAK1 MVD 1723/4885PPARD 3635/4885CHRM2 4857/4885
US-20170158683-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY JAK3, JAK2, JAK1 MVD 1723/4885PPARD 3635/4885CHRM2 4857/4885
US-20160022622-A1 LIPID COMPOSITIONS CONTAINING BIOACTIVE FATTY ACIDS ALOX5, ALOX15B, FASN MVD 939/4885PPARD 710/4885CHRM2 3242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.